Compare GCBC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | SPRY |
|---|---|---|
| Founded | 1889 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.0M | 509.4M |
| IPO Year | 1998 | 2020 |
| Metric | GCBC | SPRY |
|---|---|---|
| Price | $33.90 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 28.7K | ★ 2.4M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 26.21 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | $4,117,000.00 | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | $19.71 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $21.25 | $4.91 |
| 52 Week High | $36.02 | $15.09 |
| Indicator | GCBC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 48.72 |
| Support Level | $31.76 | $4.91 |
| Resistance Level | $33.99 | $8.61 |
| Average True Range (ATR) | 0.86 | 0.42 |
| MACD | -0.17 | 0.17 |
| Stochastic Oscillator | 28.96 | 84.47 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.